BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN

被引:28
|
作者
Deng, Rong [1 ]
Guo, Yanmin [1 ]
Li, Lian [1 ]
He, Jianfeng [1 ]
Qiang, Zhe [1 ]
Zhang, Hailong [1 ]
Chen, Ran [1 ]
Wang, Yanli [1 ]
Zhao, Xian [1 ,2 ]
Yu, Jianxiu [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, State Key Lab Oncogenes & Related Genes, Sch Med,Shanghai Key Lab Tumor Microenvironm &, Shanghai 200025, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Basic Clin Res Ctr, Sch Med, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
BAP1; cancer progression; deubiquitination; prostate cancer; PTEN; PREVENTS CHROMOSOME INSTABILITY; TUMOR-SUPPRESSOR; E3; LIGASE; CELL-PROLIFERATION; UBIQUITIN LIGASE; GENE; MUTATION; BREAST; COMPLEX; SUMOYLATION;
D O I
10.1002/1878-0261.12844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deubiquitinase BAP1 is an important tumor suppressor in several malignancies, but its functions and critical substrates in prostate cancer (PCa) remain unclear. Here, we report that the mRNA and protein expression levels of BAP1 are downregulated in clinical PCa specimens. BAP1 can physically bind to and deubiquitinate PTEN, which inhibits the ubiquitination-mediated degradation of PTEN and thus stabilizes PTEN protein. Ectopically expressed BAP1 in PCa cells increases PTEN protein level and subsequently inhibits the AKT signaling pathway, thus suppressing PCa progression. Conversely, knockdown of BAP1 in PCa cells leads to the decrease in PTEN protein level and the activation of the Akt signaling pathway, therefore promoting malignant transformation and cancer metastasis. However, these can be reversed by the re-expression of PTEN. More importantly, we found that BAP1 protein level positively correlates with PTEN in a substantial fraction of human cancers. These findings demonstrate that BAP1 is an important deubiquitinase of PTEN for its stability and the BAP1-PTEN signaling axis plays a crucial role in tumor suppression.
引用
收藏
页码:279 / 298
页数:20
相关论文
共 50 条
  • [41] BAP1 as a guardian of genome stability: implications in human cancer
    Jongbum Kwon
    Daye Lee
    Shin-Ai Lee
    Experimental & Molecular Medicine, 2023, 55 : 745 - 754
  • [42] An Emerging Model for BAP1’s Role in Regulating Cell Cycle Progression
    Ziad M. Eletr
    Keith D. Wilkinson
    Cell Biochemistry and Biophysics, 2011, 60 : 3 - 11
  • [43] Pten dose dictates cancer progression in the prostate
    Trotman, LC
    Niki, M
    Dotan, ZA
    Koutcher, JA
    Di Cristofano, A
    Xiao, A
    Khoo, AS
    Roy-Burman, P
    Greenberg, NM
    Van Dyke, T
    Cordon-Cardo, C
    Pandolfi, PP
    PLOS BIOLOGY, 2003, 1 (03) : 385 - 396
  • [44] TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN
    Qiang Qiu
    Yuanyuan Sun
    Linyu Yang
    Qingqing Li
    Yunyu Feng
    Mengyuan Li
    Yuexia Yin
    Li Zheng
    Ning Li
    Huandi Qiu
    Xue Cui
    Wei He
    Bochuan Wang
    Cong Pan
    Zi Wang
    Juan Huang
    Klarke M. Sample
    Zhihui Li
    Yiguo Hu
    Signal Transduction and Targeted Therapy, 8
  • [45] TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN
    Qiu, Qiang
    Sun, Yuanyuan
    Yang, Linyu
    Li, Qingqing
    Feng, Yunyu
    Li, Mengyuan
    Yin, Yuexia
    Zheng, Li
    Li, Ning
    Qiu, Huandi
    Cui, Xue
    He, Wei
    Wang, Bochuan
    Pan, Cong
    Wang, Zi
    Huang, Juan
    Sample, Klarke M. M.
    Li, Zhihui
    Hu, Yiguo
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [46] The BAP1 deubiquitinase promotes triple-negative breast cancer partially by stabilizing the KLF5 transcription factor
    Chen, Ceshi
    Qin, Junying
    Zhou, Zhongmei
    CANCER RESEARCH, 2015, 75
  • [47] BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer
    Yuan, Weiwei
    Zhang, Qiyue
    Zhao, Yuhan
    Xia, Wentao
    Yin, Shilin
    Liang, Xueyi
    Chen, Taoyu
    Li, Gaofeng
    Liu, Yanshen
    Liu, Zhiqiang
    Huang, Jinxi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [48] Targeting BAP1 with small compound inhibitor for colon cancer treatment
    Kang, Minhwa
    Park, Seul Gi
    Lee, Shin-Ai
    Kim, Soyi
    Lee, Daye
    Shirbhate, Mukesh Eknath
    Youn, So-Yeon
    Kim, Kwan Mook
    Cha, Sun-Shin
    Kwon, Jongbum
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [49] Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma
    Masoomian, Babak
    Shields, Jerry A.
    Shields, Carol L.
    JOURNAL OF CURRENT OPHTHALMOLOGY, 2018, 30 (02): : 102 - 109
  • [50] The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics
    O Abdel-Wahab
    A Dey
    Leukemia, 2013, 27 : 10 - 15